RxDoctor Payments Data

Paul Dang, MD

Internal Medicine · Germantown, TNNPI 1407884760

Payments from drug & device makers

$3,452in general payments, 2019–2025

Across 179 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$498
  • Dexcom, Inc.$397
  • Novo Nordisk$360
  • Amgen$360
  • AstraZeneca$335
  • Pfizer$210
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,443100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,452 in reported general payments places this provider in the 80th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$138,308
Medicare patients
311
Services billed
4,693

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$62,861
OzempicSemaglutide58$61,061
JanuviaSitagliptin Phosphate56$57,874
JardianceEmpagliflozin30$38,784
FarxigaDapagliflozin Propanediol26$26,853
MounjaroTirzepatide15$23,486
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$22,631
XareltoRivaroxaban19$18,330
WegovySemaglutide12$18,234
JanumetSitagliptin Phos/Metformin Hcl15$14,198
SantylCollagenase Clostridium Hist.12$12,960
Repatha SureclickEvolocumab11$5,873
Atorvastatin Calcium464$4,714
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$4,363
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$4,219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$360$79,29570 claims
MerckJanuvia, Janumet$11$72,07271 claims
PfizerEliquis, Paxlovid$210$64,29174 claims
Boehringer IngelheimJardiance$193$38,78430 claims
AstraZenecaFarxiga$335$26,85326 claims
Lilly USA, LLCMounjaro$498$23,48615 claims
GSKTrelegy Ellipta$85$22,63131 claims
Johnson & JohnsonXarelto$150$18,33019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →